Exhibit 99.1 TransMedics Reports First Quarter 2025 Financial Results Andover, Mass. – May 8, 2025 – TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights "Overall, we are very pleased with our first quarter performance, which we believe underscores the unique attributes of our busines ...

Core Insights - TransMedics Group, Inc. reported strong financial performance for Q1 2025, with total revenue of $143.5 million, representing a 48% increase from $96.9 million in Q1 2024, driven by increased utilization of the Organ Care System (OCS) and logistics services [2][5] - The company raised its full-year 2025 revenue guidance to a range of $565 million to $585 million, indicating a 30% growth at the midpoint compared to the previous year's revenue [6] Financial Performance - Total revenue for Q1 2025 was $143.5 million, a 48% increase compared to $96.9 million in Q1 2024, primarily due to increased OCS utilization in liver and heart transplants [2] - Gross margin for Q1 2025 was 61%, slightly down from 62% in Q1 2024, but up from 59% in Q4 2024, attributed to a higher proportion of service revenue [3] - Operating expenses for Q1 2025 were $60.8 million, up from $47.5 million in Q1 2024, driven by increased research and development investments and organizational growth [4] - Net income for Q1 2025 was $25.7 million, or 18% of revenue, compared to $12.2 million in Q1 2024 [5] Strategic Developments - The company announced plans to open a design center of excellence and a new disposables manufacturing facility in Mirandola, Italy [7] - TransMedics hosted an annual symposium at the ISHLT 45th Annual Meeting, showcasing the clinical value of OCS and NOP through 10 abstracts and presentations [7] Operational Highlights - As of March 31, 2025, TransMedics owned 21 aircraft, supporting its logistics capabilities for organ transportation [7] - Cash reserves stood at $310.1 million as of March 31, 2025, reflecting a strong liquidity position [5]

Core Insights - TransMedics (TMDX) is expected to report quarterly earnings of $0.29 per share, reflecting a decline of 17.1% year over year, while revenues are forecasted to reach $123.56 million, an increase of 27.6% year over year [1] Group 1: Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating analysts' reassessment of their projections [1][2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong relationship between earnings estimate revisions and short-term price performance [2] Group 2: Revenue Projections - Analysts project 'Net revenue by OCS product- OCS Lung net revenue' to be $5.19 million, indicating a decline of 8.4% year over year [4] - The consensus estimate for 'Net revenue by OCS product- OCS Liver net revenue' is $87.87 million, reflecting an increase of 31.3% from the previous year [4] - Estimated 'Net revenue by OCS product- OCS Heart net revenue' is $30.01 million, suggesting a year-over-year increase of 28.6% [4] Group 3: Geographic Revenue Estimates - Analysts expect 'Geographic Revenues- United States' to be $119.11 million, indicating a growth of 29.7% from the prior year [5] - The estimate for 'Geographic Revenues- All other countries' is projected at $4.09 million, reflecting a slight decline of 0.1% from the previous year [5] Group 4: Stock Performance - Shares of TransMedics have increased by 33% over the past month, outperforming the Zacks S&P 500 composite, which saw a 0.4% increase [6] - TransMedics holds a Zacks Rank 3 (Hold), suggesting it is expected to mirror overall market performance in the near future [6]

Core Viewpoint - The recent decline in TransMedics Group's shares presents a potential buying opportunity for long-term investors, despite short-term challenges and market volatility [2][6][16] Company Overview - TransMedics Group specializes in medical technology, particularly the Organ Care System (OCS), which preserves donor organs for transplantation [3][4] - The OCS mimics human physiology, significantly improving the viability of organs compared to traditional cold storage methods [4][11] Recent Performance - TransMedics' shares have dropped by 31% over the past six months due to disappointing quarterly updates, lowered guidance, and a critical report from a short-seller [2][6] - The company turned a profit last year, indicating strong revenue generation capabilities [4] Market Potential - The number of organ donors is expected to grow, with a conservative compound annual growth rate (CAGR) of 5% and an optimistic projection of 12% through 2028 [10] - TransMedics' OCS shows a significant advantage in organ utilization rates, with 87% of organs preserved through OCS being used for transplants compared to only 23% for those stored via cold storage [12] Investment Considerations - The recent sell-off may be justified by slowing revenue growth as the company matures, but the stock is now at a low point not seen in three years [13] - Investors are advised to be cautious of short-seller claims without substantial evidence [15] - TransMedics Group is viewed as a strong long-term investment opportunity for those willing to hold for a decade [16]

In the last six months, TransMedics Group Inc (NASDAQ: TMDX ) stock has fallen more than 50% from its ATH in 2024 due to missing expectations in both earnings and revenue amid Hi! I'm a passionate investor who has been researching publically traded companies for over 6 years. My primary focus is on identifying great businesses at reasonable prices and holding them for the long term. While I have a slight bias toward technology companies, I maintain a broad perspective, including opportunities in crypto. I t ...

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Investors have until April 15, 2025, to ask the Court to b ...

Core Viewpoint - The article emphasizes that despite recent market volatility, it is an opportune time for active investment, particularly in five identified companies that analysts recommend increasing their positions in [2][3]. Group 1: Nu Holdings (NU) - NU has strong earnings, with its current price providing a great investment opportunity despite external factors like the trade war and currency fluctuations affecting its perceived performance [4]. - NU's price-to-sales ratio is 3.3, and its average revenue per active customer (ARPAC) has increased by 23% year-over-year, indicating strong customer retention and growth potential in the Latin American fintech market [4]. Group 2: Lemonade (LMND) - LMND is disrupting a large market with a current price-to-earnings ratio of 3.2 and a year-over-year revenue growth of 29%, making it an attractive investment from a valuation perspective [6]. - The company has significant growth opportunities in the auto insurance market, which management believes could represent a tenfold opportunity, and it is also focusing on international and domestic expansion [6][7]. Group 3: TransMedics (TMDX) - TMDX has seen a significant stock price drop from $166 to $67, but recent earnings reports indicate strong demand for its products, with expected revenue growth of 15-20% compared to previous quarters [7]. - The company is likely to exceed market expectations, which could lead to a positive revision of its earnings guidance for fiscal year 2025 [7]. Group 4: Amazon (AMZN) - Amazon has shown strong performance with an 11% year-over-year revenue growth and an increase in free cash flow margin to 9.5% [8]. - The company is projected to dominate key markets such as e-commerce, cloud services, and digital advertising, with significant growth opportunities estimated for 2040 [9][10]. Group 5: MercadoLibre (MELI) - MercadoLibre, often referred to as the Amazon of Latin America, holds a substantial market share in e-commerce, logistics, fintech, and advertising [11]. - The Latin American e-commerce market is valued at $350 billion, with MercadoLibre capturing approximately 30% of this market, translating to a potential market opportunity of $420 billion [12].

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $121.6 million, representing approximately 50% growth year-over-year and 12% sequential growth from Q3 2024 [17][40] - Full year 2024 total revenue reached $441.5 million, representing approximately 83% growth over full year 2023 [19][49] - Overall gross margin for Q4 improved to 59%, up from 56% in Q3 2024 [18] - Operating profit for Q4 was $8.6 million, representing approximately 7.1% of total revenue, up from $3.9 million or 4% of total revenue in Q3 2024 [18][47] - Full year gross margin was 59.4%, down from 63.8% in 2023 due to a higher contribution of service revenue [20][52] Business Line Data and Key Metrics Changes - TransMedics transplant logistics service revenue for Q4 was $21.7 million, up from $9.2 million in Q4 2023 and up from $20.1 million in Q3 2024, representing approximately 8% sequential growth [18][41] - Product revenue for Q4 increased to $74.9 million, reflecting a 44.5% year-over-year growth [40] - Service revenue reached $46.7 million, growing 59.3% year-over-year [41] Market Data and Key Metrics Changes - U.S. revenue grew 11% sequentially to $117 million, while OUS revenue grew approximately 51% sequentially to $4 million [17] - For the full year 2024, U.S. revenue grew to $422 million, representing approximately 91% growth over the full year 2023 [19] - Overall U.S. OCS market share across all three organs was 20.9% for the full year 2024, up from 13.8% in 2023 [22] Company Strategy and Development Direction - The company aims to expand the utilization of available donor organs for transplantation while delivering the best possible clinical outcomes [8] - Future growth will be driven by the launch of next-gen heart and lung clinical programs targeted for H2 2025 [27][33] - The company plans to strategically invest in business infrastructure to ensure scalability while maintaining quality and reducing supply chain risks [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2025, expecting revenue guidance between $530 million and $552 million, representing a 20% to 25% growth over full year 2024 [36][55] - The company acknowledged operational challenges, including unexpected aircraft maintenance impacting availability and variability in organ transplantation volume [35] - Management emphasized the importance of educating the public about organ transplant challenges and the company's commitment to improving clinical outcomes [81] Other Important Information - The company conducted an independent investigation regarding allegations raised in a short report, which found no evidence of fraud or misconduct [10][12] - Total cash at the end of the quarter was $336.7 million, a decrease of $58.2 million from December 31, 2023 [48] Q&A Session Summary Question: Thoughts on seasonality and quarter-to-quarter variability - Management noted that they do not issue quarter-to-quarter guidance but acknowledged that variability is common in the transplant market, particularly in Q3 and Q4 [64][65] Question: Growth trajectories for organ-specific revenue - Management indicated that liver will continue to lead growth until contributions from heart and lung clinical programs are realized in the second half of 2025 [68][69] Question: Confidence in high-volume customers - Management reassured that concerns about customer attrition were unfounded, citing active usage by previously mentioned centers [72] Question: Impact of competitive risks from NRP approach - Management stated that NRP is not seen as a threat to their liver DCD franchise, with market share increasing to 53% [75] Question: Commentary on organ allocation issues - Management expressed encouragement about public awareness of organ transplant challenges but clarified that the issues highlighted do not significantly impact their business [83] Question: Guidance for Q1 and contribution from clinical trials - Management estimated that the contribution from clinical trials to revenue growth would be between 2% to 5% [90][92] Question: Scope and independence of the independent review - Management confirmed that the review was exhaustive and reported to the audit committee, but did not disclose further details [104] Question: Confidence in share gains for 2025 - Management expressed confidence in continued share gains, citing significant growth in market share despite external noise [108] Question: Capacity and logistics utilization - Management emphasized the importance of optimizing operations and maintaining capacity to handle demand fluctuations [112] Question: R&D spending growth expectations - Management indicated that R&D spending will continue to grow, focusing on OCS innovation and next-generation technology [117]